The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year




Total Raised


Market Cap


Stock Price




About Second Sight Medical Products

Second Sight Medical Products manufactures and markets implantable visual prosthetics to enable blind individuals to achieve greater independence. The Argus II Retinal Prosthesis System ("Argus II") is an approved device intended to restore some functional vision for people suffering from blindness. Argus II is approved for use in the United States and the European Economic Area.

Second Sight Medical Products Headquarter Location

12744 San Fernando Road Bldg 3

Sylmar, California, 91342,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Second Sight Medical Products

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Second Sight Medical Products is included in 1 Expert Collection, including Digital Health.


Digital Health

12,795 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

Second Sight Medical Products Patents

Second Sight Medical Products has filed 241 patents.

The 3 most popular patent topics include:

  • Implants (medicine)
  • Neuroprosthetics
  • Prosthetics
patents chart

Application Date

Grant Date


Related Topics




Implants (medicine), Prosthetics, Neuroprosthetics, Blindness, Augmented reality applications


Application Date


Grant Date



Related Topics

Implants (medicine), Prosthetics, Neuroprosthetics, Blindness, Augmented reality applications



Latest Second Sight Medical Products News

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Second Sight Medical Products, Inc. Merger

Feb 18, 2022

Wilmington, Delaware--(Newsfile Corp. - February 18, 2022) - Rigrodsky Law, P.A. announces that it is investigating Second Sight Medical Products, Inc. ("Second Sight") (NASDAQ: EYES) regarding possible breaches of fiduciary duties and other violations of law related to Second Sight's agreement to be acquired by Nano Precision Medical, Inc. ("Nano"). Under the terms of the agreement, Nano's shareholders will receive a total of 134 million shares of Second Sight common stock. To learn more about this investigation and your rights, visit: . You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or . Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide. Attorney advertising. Prior results do not guarantee a similar outcome. CONTACT:

Second Sight Medical Products Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Second Sight Medical Products Rank

  • When was Second Sight Medical Products founded?

    Second Sight Medical Products was founded in 1998.

  • Where is Second Sight Medical Products's headquarters?

    Second Sight Medical Products's headquarters is located at 12744 San Fernando Road, Sylmar.

  • What is Second Sight Medical Products's latest funding round?

    Second Sight Medical Products's latest funding round is PIPE.

  • How much did Second Sight Medical Products raise?

    Second Sight Medical Products raised a total of $34.9M.

  • Who are the investors of Second Sight Medical Products?

    Investors of Second Sight Medical Products include Gregg Williams, Versant Ventures and Emergent Medical Partners.

  • Who are Second Sight Medical Products's competitors?

    Competitors of Second Sight Medical Products include AcuFocus, SOLX, Atria Medical, EyeTechCare, AqueSys and 12 more.

You May Also Like

NovaLign Orthopaedics

NovaLign Orthopaedics, formerly known as OsteoLign, is developing a minimally invasive solution for long bone fractures.


AcuFocus is an ophthalmic medical device company that develops and markets technologies for the improvement of near vision. The company's technology platform uses a small aperture - or pinhole - effect to allow focused light rays to reach the retina and bring objects into focus. Using this small aperture concept, two products have been developed: the Company's flagship product, the KAMRA corneal inlay, and the IC-8 IOL. The KAMRA inlay helps presbyopic patients restore their near vision while maintaining their distance vision. The IC-8 IOL* is specifically designed for patients with cataracts. In addition to these products, AcuFocus also distributes the AcuTarget HD diagnostic and surgical planning instrument. This instrument is used for a range of patients, including LASIK, cataract, dry eye and presbyopes.


Beta-Stim - Minimally invasive implantable neuro-stimulator to treat obesity and type II diabetic patients.


EyeTechCare is developing non-invasive therapeutic medical devices for the ophthalmology market based on High-Intensity Focused Ultrasound (HIFU), a technology that allows ambulatory and rapid treatment to be performed, thereby limiting the cost and the risk to the patient. The company's first device, EyeOP1 (R), for the treatment of glaucoma, has been undergoing clinical trials in France and Europe.


Satiety, Inc. is a medical device company focused on the development of less invasive devices for the treatment of obesity. Obesity is a global health problem, affecting 70 million people in the U.S. and 300 million worldwide, and growth of which is causing increases in obesity-related diseases such as diabetes, high blood pressure and cardiovascular disease. Obesity surgery has been shown to be the only long-term effective means of weight loss for morbidly obese patients. Satiety's first product, the TOGA System, enables physicians to perform a procedure similar to traditional restrictive obesity surgeries, but without surgical incisions. In this procedure, the TOGA System devices are inserted transorally (through the mouth) and are used to reduce the capacity of the stomach to give patients a feeling of fullness after a small meal. The procedure is intended to be safer and easier for patients to tolerate than conventional obesity surgery. Safety and effectiveness of the TOGA System are currently being evaluated in a multi-center U.S. Study and the system is not available for sale in the United States.

Angel Medical Systems Logo
Angel Medical Systems

Angel Medical Systems has developed the AngelMed Guardian system, an implantable cardiac monitoring and alerting system that is designed to warn cardiac patients of potentially life-threatening heart conditions. The AngelMed Guardian System heart monitor is designed to track changes in the heart's electrical signal from a standard pacemaker lead, identify the signature of acute thrombotic occlusions when they occur, and then alert the patient directly to seek medical attention. The device is being studied in high risk heart patients who do not qualify for an ICD, but who have had a STEMI, NSTEMI or unstable angina in their recent past.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.